PD-1/PD-L1抑制剂-话题@MedSci

#PD-1/PD-L1抑制剂#

9篇内容 | 851人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1388141, encodeId=416c1388141e8, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂, objectType=article, longId=736109, objectId=7fe7e3610956, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fe7e3610956, replyNumber=0, likeNumber=34, createdTime=2022-08-19, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fe7e3610956, moduleTitle=JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fe7e3610956)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388140, encodeId=83c913881405c, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, objectType=article, longId=295140, objectId=2fc82951409c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fc82951409c, replyNumber=0, likeNumber=37, createdTime=2022-02-06, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fc82951409c, moduleTitle=Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fc82951409c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388139, encodeId=471b13881391f, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, objectType=article, longId=215780, objectId=dc30215e8019, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc30215e8019, replyNumber=0, likeNumber=34, createdTime=2021-08-17, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc30215e8019, moduleTitle=Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc30215e8019)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388138, encodeId=c173138813894, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=Nat Commun：抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性, objectType=article, longId=200773, objectId=f5e6200e73e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5e6200e73e3, replyNumber=0, likeNumber=44, createdTime=2020-09-18, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5e6200e73e3, moduleTitle=Nat Commun：抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5e6200e73e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388137, encodeId=cacd138813ec2, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=国内PD-1/PD-L1抑制剂亟需冷静, objectType=article, longId=179967, objectId=0ce11e9967da, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ce11e9967da, replyNumber=0, likeNumber=41, createdTime=2019-09-26, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ce11e9967da, moduleTitle=国内PD-1/PD-L1抑制剂亟需冷静, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ce11e9967da)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388136, encodeId=93b2138813661, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇, objectType=article, longId=163480, objectId=b6cb163480f2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b6cb163480f2, replyNumber=0, likeNumber=35, createdTime=2019-04-04, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b6cb163480f2, moduleTitle=宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b6cb163480f2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388135, encodeId=d03313881356e, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, objectType=article, longId=154370, objectId=61761543e050, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61761543e050, replyNumber=0, likeNumber=37, createdTime=2018-11-27, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61761543e050, moduleTitle=JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61761543e050)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388134, encodeId=9e0e1388134f9, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, objectType=article, longId=149879, objectId=d9c41498e99b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9c41498e99b, replyNumber=0, likeNumber=35, createdTime=2018-09-30, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9c41498e99b, moduleTitle=马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9c41498e99b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1388133, encodeId=479c1388133ee, content=<a href='/topic/show?id=779d1389e7e' target=_blank style='color:#2F92EE;'>#PD-1/PD-L1抑制剂#</a>, objectTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, objectType=article, longId=101079, objectId=78e61010e913, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61010e913, replyNumber=0, likeNumber=39, createdTime=2017-05-12, rootId=0, userName=ms3117646317107274, userId=97862500016, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61010e913, moduleTitle=PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e61010e913)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1/PD-L1抑制剂

2020-05-29

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

JITC：突破性进展！开发出一种有望使免疫疗法适用于所有癌症患者的小分子PD-1/PD-L1抑制剂

2022-08-19

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

Clin Cancer Res：PD-1/PD-L1抑制剂治疗失败后，NSCLC患者是否还可从派姆单抗+化疗治疗中获益？

2022-02-06

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

Lancet Oncol：以PD-1/PD-L1抑制剂为基础的不同联合方案的不良事件发生情况

2021-08-17

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

Nat Commun：抗GARP:TGF-β1单抗能克服PD-1/PD-L1抑制剂耐药性

2020-09-18

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

国内PD-1/PD-L1抑制剂亟需冷静

2019-09-26

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

宝刀尚未老，新剑已开锋——PD-1/PD-L1抑制剂的现状和新机遇

2019-04-04

zhaojie88 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

JCO：PD-1/PD-L1抑制剂初始治疗NSCLC 糖皮质激素让抗癌神药部分失效

2018-11-27

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

马军教授：PD-1/PD-L1抑制剂在淋巴瘤领域中前景无限

2018-09-30

ms3117646317107274 (审核中...)

前往app查看评论内容

#PD-1/PD-L1抑制剂#

PD-1/PD-L1抑制剂市场再添一员！阿斯利康PD-L1抑制剂Imfinzi获FDA加速批准

2017-05-12

科室
- - 订阅+
  - 更多科室
工具
服务